查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1197905

患者自控鎮痛泵市場 - 增長、趨勢、COVID-19 影響和預測 (2023-2028)

Patient-Controlled Analgesia Pumps Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 115 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

在預測期內，患者自控鎮痛 (PCA) 泵市場的複合年增長率預計為 5.2%。

COVID-19 大流行給醫療保健系統帶來了巨大挑戰。 在 COVID-19 的初始階段，由於幾個不確定的原因，患者自控鎮痛泵市場的擴張受到顯著限制。 然而，從 COVID-19 感染中康復的患者慢性疼痛的發生率正在增加。 例如，根據 2022 年 3 月的當前疼痛和頭痛報告，在美國接種 COVID-19 疫苗可能減少了新的 SARS-CoV-2 感染，但長期接觸該病毒的人數增加了。患有常見症狀的人越來越多。 其長期副作用之一是慢性疼痛綜合症。 因此，為了控制 COVID-19 康復患者的慢性疼痛，需要患者自控鎮痛泵來幫助患者控制疼痛。 預計這將在預測期內對市場產生積極影響。

市場增長的主要推動因素是關節炎、癌症和纖維肌痛等慢性疼痛疾病的患病率上升，以及與 PCA 泵安全特性增強相關的技術進步。 纖維肌痛是一種引起全身疼痛的疾病，也稱為瀰漫性疼痛。 纖維肌痛症患病率的增加將有助於患者自控鎮痛泵市場的增長。 例如，根據 CDC 2022 年 5 月的更新，大約有 400 萬美國公民（佔所有成年人的 2%）患有纖維肌痛。 雖然纖維肌痛的病因尚不清楚，但可以通過多種疼痛管理方式對其進行治療和管理，其中之一就是患者自控鎮痛泵。 因此，纖維肌痛等慢性疼痛疾病的巨大負擔將增加患者自控鎮痛泵的使用，推動研究期間的市場增長。

監管機構最近的產品發布和批准主要集中在患者自控鎮痛泵上，預計將有助於市場增長，因為這些批准增加了產品的可用性和市場競爭。 例如，2021 年 4 月，Becton Dickinson & Company 向美國 FDA 提交了 BD Alaris 系統的 510(k) 上市前通知。 該系統使臨床醫生能夠通過一個集成平台提供止痛藥和液體，該平台包括用於成人、兒科和新生兒患者的大容量泵和注射泵。 因此，預計在預測期內，受慢性疼痛疾病影響的大量人口和產品批准的增加將刺激研究市場的增長。 然而，缺乏意識、嚴格的監管框架以及導致患者用藥錯誤的相關產品召回可能會減緩預測期內的市場增長。

PCA 市場趨勢

腫瘤學有望在預測期內佔據主要市場份額

由於癌症在全球範圍內廣泛流行，預計在預測期內，癌症細分市場將佔據很大的市場份額。 癌症疼痛通常被描述為抽動、壓迫、灼痛或刺痛感，可以使用 PCA 泵來控制。 因此，隨著癌症負擔的增加，預計對 PCA 泵的需求也會增加。 例如，根據 2021 年加拿大癌症統計數據，加拿大將在 2021 年發現 229,200 例新癌症病例。 同樣，CMAJ Group 在 2022 年發布的一份報告估計，2022 年加拿大將有 233,900 人被診斷出患有癌症。 因此，該地區新癌症病例的增加將增加對疼痛管理的需求，而疼痛管理可以使用患者控制的止痛泵來實現。 因此，市場增長是可預期的。 醫生會通過患者自控鎮痛 (PCA) 輸注高活性阿片類藥物，例如氫嗎啡、嗎啡和芬太□□尼，以治療難以忍受的疼痛。 在這種情況下，越來越多地採用 PCA 泵來提高生活質量有望推動這一領域的增長。

同樣，通過使用患者自控鎮痛藥來提高患者對癌症疼痛管理的滿意度也將在市場增長中發揮重要作用。 例如，根據 2021 年 8 月發表在 JNCCN 期刊上的一篇論文，可編程患者自控鎮痛 (PCA) 泵可以幫助患者按需控制疼痛並快速響應不斷變化的患者需求，並且可以減少鎮痛藥物的延遲。 PCA 顯著降低了持續性嚴重癌症疼痛的滴定成功率和平均疼痛評分。 因此，對 PCA 泵用於癌症疼痛管理的偏好預計將推動該細分市場的增長。

預計在預測期內北美將佔據很大的市場份額

由於癌症、意外傷害和其他疼痛相關疾病的病例不斷增加，以及慢性疼痛的研究支出不斷增加，預計北美將主導整個 PCA 泵市場。

由於癌症患者比例高，預計北美地區將刺激市場增長。 例如，根據 ACS 2021 & 2022 報告，2021 年美國估計將有 1,898,160 例新癌症病例，到 2022 年將上升到 1,918,030 例。 排除黑色素瘤以外的皮膚癌，美國 42% 的新診斷癌症病例，即 2022 年的約 805,600 例，是可以預防的。 因此，預計該地區癌症患者患病率上升將在預測期內推動該地區的市場增長。

此外，慢性疼痛研究經費的增加預計也將推動該地區的市場增長。 例如，根據 NIH 2022，美國在 2021 年、2022 年和 2023 年用於慢性疼痛的研究經費預計分別為 7.25 億美元、7.5 億美元和 8.62 億美元。 該地區主要市場參與者之間的聯盟和收購也在推動市場增長。 例如，2022 年 1 月，總部位於加利福尼亞州的 ICU Medical 從 Smiths Group Plc 收購了 Smiths Medical Division，該部門包括注射器、門診輸液設備、血管通路和重要護理產品。 此類活動可能會擴大公司的投資組合，並有望在北美地區的預測期內實現顯著增長。

PCA（患者自控鎮痛）泵市場競爭對手分析

PCA（患者自控鎮痛）泵市場競爭適中，由幾家大型企業組成。 從市場份額的角度來看，一些主要參與者目前主導著市場。 一些著名的參與者使用新技術開發了安全無故障的系統，其他人也出售這些系統。 目前主導市場的公司包括 ICU Medical Inc. (Smiths Medical)、BD (Becton, Dickinson and Company)、Fresenius SE & Co. KGaA、B. Braun SE 和 Baxter。

其他福利。

  • Excel 格式的市場預測 (ME) 表
  • 3 個月的分析師支持

內容

第一章介紹

  • 研究假設和市場定義
  • 調查範圍

第二章研究方法論

第 3 章執行摘要

第四章市場動態

  • 市場概覽
  • 市場驅動力
    • 提高安全性的技術進步
    • 癌症和關節炎等慢性疼痛疾病的增加
  • 市場製約因素
    • 意識不足導致患者誤認藥物
    • 嚴格的監管框架和產品召回
  • 波特的五力分析
    • 新進入者的威脅
    • 買方/消費者議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭公司之間的敵對關係

第 5 章市場細分

  • 按產品類型
    • PCA 泵
    • 泵配件
  • 通過申請
    • 腫瘤學
    • 糖尿病
    • 新生兒科
    • 其他用途
  • 最終用戶
    • 醫院
    • 門診手術中心
    • 家庭護理
  • 區域信息
    • 北美
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 意大利
      • 西班牙
      • 其他歐洲地區
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
    • 中東
      • 海灣合作委員會
      • 南非
      • 其他中東地區
    • 南美洲
      • 巴西
      • 阿根廷
      • 其他南美洲

第六章競爭格局

  • 公司簡介
    • ICU Medical Inc.（Smiths Medical）
    • Baxter
    • BD（Becton, Dickinson and Company）
    • Fresenius SE & Co. KGaA
    • Micrel Medical Devices
    • Avante Health Solutions
    • B. Braun SE
    • Ace Medical
    • Terumo Corporation
    • Abbott
    • Pfizer Inc.（Hospira）

第7章 市場機會今後動向

簡介目錄
Product Code: 68518

The patient-controlled analgesia (PCA) pump market is expected to register a CAGR of 5.2% over the forecast period.

The healthcare system witnessed enormous challenges as a result of the COVID-19 pandemic. During the first phase of COVID-19, the expansion of the patient-controlled analgesia pump market was significantly constrained for several uncertain reasons. However, there is an increasing occurrence of chronic pain in patients who recovered from COVID-19 infection. For instance, as per the Current Pain and Headache Reports in March 2022, the vaccination for COVID-19 in the United States may be reducing the number of new SARS-CoV-2 cases, but the population of those suffering from the virus's long-term symptoms is growing. One of these long-term side effects includes chronic pain syndromes. Hence, to manage the chronic pain of COVID-19-recovered patients, there is a need for patient-controlled analgesia pumps, which help the patient control their pain. This is expected to positively impact the market over the forecast period.

The major factors attributing to the market's growth are the increasing prevalence of chronic pain diseases such as arthritis, cancer, and fibromyalgia, along with the technological advancements with enhanced safety features in the PCA pumps. Fibromyalgia is a condition that causes pain all over the body, also called widespread pain. The increase in the prevalence of fibromyalgia helps the growth of the patient-controlled analgesia pump market. For instance, according to the updated data from CDC in May 2022, about 4 million US citizens, or 2% of all adults, suffer from fibromyalgia. Although there is no known cause for fibromyalgia, it is treatable and manageable with various pain management methods, one of which is a patient-controlled analgesia pump. Hence a significant burden of chronic pain diseases like fibromyalgia increases the usage of patient-controlled analgesia pumps and drives the market's growth over the study period.

The recent product launches and approvals by the regulatory authorities focusing on patient-controlled analgesia pumps are expected to aid in the market's growth, as these approvals will increase product availability and competition in the market. For instance, in April 2021, Becton, Dickinson, and Company submitted a 510(k) premarket notification to the US FDA for the BD Alaris System. The system allows clinicians to deliver pain medications and fluids through a single integrated platform that includes large-volume pumps and syringe pumps for adult, pediatric and neonatal patients. Thus, the large population affected by chronic pain-causing diseases and the increasing product approvals are expected to add to the growth of the studied market over the forecast period. However, the lack of awareness resulting in patient medication errors and the stringent regulatory framework and associated product recalls are likely to slow down the market growth over the forecast period.

Patient-controlled Analgesia Pumps Market Trends

Oncology is Expected to Hold the Major Market Share in the Market Over the Forecast Period

The oncology segment is expected to account for a significant market share during the forecast period due to the widespread prevalence of cancers worldwide. Cancer pain is often described as a throbbing, pressing, burning, or tingling sensation that can be managed through PCA pumps, and hence, the demand for PCA pumps is expected to increase with the rising burden of cancer. For Instance, according to the Canadian Cancer Statistics 2021, in Canada, 229,200 new cancer cases were detected in 2021. Similarly, as per the report published by the CMAJ Group in 2022, an estimated 233,900 people in Canada will be diagnosed with cancer in 2022. ​Thus, the increase in new cases of cancer in the region will increase the demand for pain management, which can be achieved using patient-controlled analgesia pumps. Therefore, growth in the market is expected. Highly potent opioid drugs, such as hydro morphine, morphine, and fentanyl through patient-controlled analgesia (PCA) infusion, are prescribed by physicians to treat unbearable pain. The rising adoption of PCA pumps in such conditions to improve the quality of life is expected to promote the segment's growth.

Similarly, the increase in patient satisfaction with cancer pain management with the use of patient-controlled analgesics plays a significant role in market growth. For instance, as per an article published by the JNCCN Journal in August 2021, the programmable patient-controlled analgesia (PCA) pump allows patients to control pain on demand and also promptly responds to the patient's changing needs, and it reduces analgesic delay. The PCA significantly reduced successful titration and average pain score for persistent severe cancer pain. Thus, the preference for PCA pumps for cancer pain management is expected to boost the growth of the segment.

North America is Expected to Hold a Significant Share in the Market Over the Forecast Period

North America is expected to dominate the overall PCA pumps market owing to the rise in the number of cases of cancer, accidental injuries, and other ailments related to pain and the rise in research funding on chronic pain.

The high prevalence of cancer cases in the North American region is expected to add to the market's growth. For instance, as per the ACS 2021 & 2022 report, in the United States, 1,898,160 new cancer cases were estimated in 2021, which is going to rise in 2022 to 1,918,030 new cancer cases. Excluding non-melanoma skin cancer, 42% of cancer cases in the United States that are newly diagnosed, or around 805,600 cases in 2022, may be preventable. Thus, the rising prevalence of cancer cases in the region is likely to boost the market's growth in the region over the forecast period.

Furthermore, the rise in research funding on chronic pain is also expected to propel the market's growth in the region. For instance, as per NIH 2022, the research funding for chronic pain in the United States for 2021, 2022, and 2023 is estimated at USD 725 million, USD 750 million, and USD 862 million, respectively. In addition, the partnerships and acquisitions among the key market players in the region are also adding to the market's growth. For instance, in January 2022, California-based ICU Medical acquired the Smiths Medical Division, which includes syringe and ambulatory infusion devices, vascular access, and vital care products from Smiths Group Plc. Such activities are likely to expand the portfolio of companies, which are expected to witness significant growth over the forecast period in the North American region.

Patient-controlled Analgesia Pumps Market Competitor Analysis

The PCA pumps market is moderately competitive and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. Some prominent players are developing safe and trouble-free systems with novel technologies, while others are distributing them. Some of the companies that are currently dominating the market are ICU Medical Inc. (Smiths Medical), BD (Becton, Dickinson and Company), Fresenius SE & Co. KGaA, B. Braun SE, and Baxter.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Technological Advancements with Enhanced Safety Features
    • 4.2.2 Rising Prevalence of Chronic Pain Diseases like Cancer and Arthritis
  • 4.3 Market Restraints
    • 4.3.1 Lack of Awareness Resulting in Patient Medication Errors
    • 4.3.2 Stringent Regulatory Framework and Product Recalls
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Product Type
    • 5.1.1 PCA Pumps
    • 5.1.2 Pump Accessories
  • 5.2 By Application
    • 5.2.1 Oncology
    • 5.2.2 Diabetes
    • 5.2.3 Neonatology
    • 5.2.4 Other Applications
  • 5.3 By End Users
    • 5.3.1 Hospital
    • 5.3.2 Ambulatory Surgical Centers
    • 5.3.3 Home-care Settings
  • 5.4 By Geography
    • 5.4.1 North America
      • 5.4.1.1 United states
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 ICU Medical Inc. (Smiths Medical)
    • 6.1.2 Baxter
    • 6.1.3 BD (Becton, Dickinson and Company)
    • 6.1.4 Fresenius SE & Co. KGaA
    • 6.1.5 Micrel Medical Devices
    • 6.1.6 Avante Health Solutions
    • 6.1.7 B. Braun SE
    • 6.1.8 Ace Medical
    • 6.1.9 Terumo Corporation
    • 6.1.10 Abbott
    • 6.1.11 Pfizer Inc. (Hospira)

7 MARKET OPPORTUNITIES AND FUTURE TRENDS